Efficiency and acceptability of two-stage therapy for recurrent bacterial vaginosis
Objective: To evaluate the clinical and laboratory efficiency, acceptability, and safety of anti-relapse therapy with a cream containing acidophilic bacteria (Lactobacillus acidophilus), vitamin-mineral protein-peptide complex (Superlimflife) in patients with bacterial vaginosis (BV) Materials and methods: One hundred and sixteen women aged 18 to 49 years with recurrent BV were examined. The diagnosis was based on Amsel’s criteria. After assessing the inclusion and exclusion criteria, 100 women were included in the study. The patients were divided into 2 groups: 1) 50 patients with recurrent BV who were prescribed one-stage therapy; 2) 50 patients with recurrent BV who were prescribed two-stage therapy using Acylact DUO cream. The urogenital tract microflora was comprehensively studied using real-time PCR. The expression profiling method was used to evaluate the state of local (mucosal) immunity by the mRNA expression levels of the key immune response genes. The expression level of 8 genes, such as IL-1ß, IL-10, IL-18, TNFa, TLR4, GATA3, CD68, and B2M, was taken into account in the epithelial cell sample, by using the ImmunoQuantex kit. Results: The findings suggest that the number of complaints in the patients who received two-stage therapy at Visit 4, while their recurrence occurred after one-stage therapy. Microscopic examination of vaginal smears by Visit 4 revealed that the predominance of the Lactobacillus spp. morphotype and the absence of key cells were more common in the patients receiving anti-relapse therapy than in those having one-stage therapy (p<0.05). In Group 2 women who received two-stage therapy by Visit 4, the number of lactobacilli in 45 (90%) women corresponded to the normal value, moderate and significant decreases in lactobacilli were found in 2 (4%) and 3 (6%) patients, respectively; while in Group 1 by Visit 4, the normal number of lactobacilli was observed in 22 (44%) women; moderate or significant decrease were seen in 16 (32%) and 12 (24%) patients, respectively. Analyzing the time course of changes in the expression level of proinflammatory and anti-inflammatory cytokines in each of the groups during 4 visits revealed that the women in the two-stage group had a tendency to decrease proinflammatory markers and to increase anti-inflammatory ones (p<0.05). On the contrary, the women having one-stage therapy showed a decrease in the expression level of anti-inflammatory markers and an increase in that of TLR4 and TNFA compared to the screening stage; while the expression level of IL8, IL10, and TLR2 decreased (p < 0.05). Conclusion: Two-stage therapy using the Acylact DUO cream enhances the efficiency of antibacterial therapy in combined use due to the normalization of a local immune response, contributes to a more stable restoration of the normal representative ratio for the vaginal microbiota and to a decrease in the rate of the recurrent process.Uruimagova A.T., Prilepskaya V.N., Mezhevitinova E.A., Donnikov A.E., Abakarova P.R., Dovletkhanova E.R., Gusakov K.I., Odyvanova A.A.
Keywords
vaginal microflora
bacterial vaginosis
recurrent BV
probiotics
acidophilic bacteria
Acylact DUO
References
- Integrative HMP (iHMP) Research Network Consortium. The integrative human microbiome project. Nature. 2019; 569(7758): 641-8. https://dx.doi.org/10.1038/s41586-019-1238-8.
- Dominguez-Bello M.G., Costello E.K., Contreras M., Magris M., Hidalgo G., Fierer N., Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl. Acad. Sci. USA. 2010; 107(26): 11971-5. https://dx.doi.org/10.1073/pnas.1002601107.
- Koenig J.E., Spor A., Scalfone N., Fricker A.D., Stombaugh J., Knight R. et al. Succession of microbial consortia in the developing infant gut microbiome. Proc. Natl. Acad. Sci. USA. 2010; 108(Suppl. 1): 4578-85. https://dx.doi.org/10.1073/pnas.1000081107.
- Yatsunenko T., Rey F.E., Manary M.J., Trehan I., Dominguez-Bello M.G. et al. Human gut microbiome viewed across age and geography. Nature. 2012; 486(7402): 222-7. https://dx.doi.org/10.1038/nature11053.
- Gajer P., Brotman R.M., Bai G., Sakamoto J., Schütte U.M.E., Zhong X. et al. Temporal dynamics of the human vaginal microbiota. Sci. Transl. Med. 2012; 4(132): 132ra52. https://dx.doi.org/10.1126/scitranslmed.3003605.
- Faith J.J., Guruge J.L., Charbonneau M., Subramanian S., Seedorf H., Goodman A.L. et al. The long-term stability of the human gut microbiota. Science. 2013; 341(6141): 1237439. https://dx.doi.org/10.1126/science.1237439.
- Haahr T., Jensen J.S., Thomsen L., Duus L., Rygaard K., Humaidan P. Abnormal vaginal microbiota may be associated with poor reproductive outcomes: a prospective study in IVF patients. Hum. Reprod. 2016; 31(4): 795‐803. https://dx.doi.org/10.1093/humrep/dew026.
- Brown R.G., Marchesi J.R., Lee Y.S., Smith A., Lehne B. et al. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Med. 2018; 16(1): 9. https://dx.doi.org/10.1186/s12916-017-0999-x.
- Менухова Ю.Н. Бактериальный вагиноз: этиопатогенез, клинико-лабораторные особенности. Журнал акушерства и женских болезней. 2013; 62(4): 79-87. [Menuhova Yu.N. Bacterial vaginosis: etiopathogenesis, clinical and laboratory features. Journal of Obstetrics and Women's Diseases. 2013; 4: 79-87. (in Russian)].
- Филимонова Т.М., Елисютина О.Г., Ниязов Д.Д., Болдырева М.Н., Бурменская О.В., Реброва О.Ю. Локальный и системный иммунный ответ у больных тяжелым атопическим дерматитом. Российский аллергологический журнал. 2011; 5: 10-5. [Filimonova T.M., Elisyutina O.G., Niyazov D.D., Boldyreva M.N., Burmenskaya O.V., Rebrova O.Yu. Local and systemic immune response in patients with severe atopic dermatitis. Russian Allergological Journal. 2011; 5: 10-5. (in Russian)].
- Долгушина В.Ф., Смольникова Л.А., Долгушин И.И. Состояние факторов местной иммунной защиты репродуктивного тракта при вагинозе у беременных. Журнал микробиологии, эпидемиологии и иммунобиологии. 2001; 4: 89-93. [Dolgushina V.F., Smol'nikova L.A., Dolgushin I.I .Factors of the local immune defence of the reproductive tract in pregnant women with vaginosis. Journal of Microbiology, Epidemiology and Immunobiology. 2001; 4: 89‐93. (in Russian)].
- Kalia N., Singh J., Kaur M. Immunopathology of recurrent vulvovaginal infections: new aspects and research directions. Front. Immunol. 2019; 10: 2034. https://dx.doi.org/10.3389/fimmu.2019.02034.
- Centers for Disease Control and Prevention. STD Treatment Guidelines. 2021.
- Reid G. Has knowledge of the vaginal microbiome altered approaches to health and disease? F1000Res. 2018; 7: 460. https://dx.doi.org/10.12688/f1000research.13706.1.
- Sherrard J., Wilson J., Donders G., Mendling W., Jensen J.S. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int. J. STD AIDS. 2018; 29(13): 1258-72. https://dx.doi.org/10.1177/0956462418785451.
- Радзинский В.Е., Ордиянц И.М., Четвертакова Э.С., Мисуно О.А. Двухэтапная терапия вагинальных инфекций. Акушерство и гинекология. 2011; 5: 78-81. [Radzinsky V.E., Ordiyants I.M., Chetvertakova E.S., Misuno O.A. Two-stage therapy of vaginal infections. Obstetrics and Gynecology. 2011; 5: 78-81. (in Russian)].
- Прилепская В.Н., Кира Е.Ф., Гомберг М.А., Аполихина И.А., Байрамова Г.Р. Федеральные клинические рекомендации. Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями из половых путей женщин. М.; 2019. 50с. [Prilepskaya V.N., Kira E.F., Gomberg M.A., Apolikhina I.A., Bayramova G.R. Federal clinical guidelines. Diagnostics and treatment of diseases accompanied by pathological discharge from the genital tract of women. M.; 2019. 50p. (in Russian)].
- Bradshaw C.S., Sobel J.D. Current treatment of bacterial vaginosis-limitations and need for innovation. J. Infect. Dis. 2016; 214(Suppl. 1): S14-20. https://dx.doi.org/10.1093/infdis/jiw159.
- Wilson J. Managing recurrent bacterial vaginosis. Sex. Transm. Infect. 2004; 80(1): 8-11. https://dx.doi.org/10.1136/sti.2002.002733.
- Muzny C.A., Kardas P. A narrative review of current challenges in the diagnosis and management of bacterial vaginosis. Sex. Transm. Dis. 2020; 47(7): 441-6. https://dx.doi.org/10.1097/OLQ.0000000000001178.
- Coudray M.S., Madhivanan P. Bacterial vaginosis – a brief synopsis of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 245: 143-8. https://dx.doi.org/10.1016/j.ejogrb.2019.12.035.
- Marcone V., Calzolari E., Bertini M. Effectiveness of vaginal administration of Lactobacillus rhamnosus following conventional metronidazole therapy: how to lower the rate of bacterial vaginosis recurrences. New Microbiol. 2008; 31(3): 429-33.
- Lopez-Moreno A., Aguilera M. Vaginal probiotics for reproductive health and related dysbiosis: Systematic review and meta-analis. J. Clin. Med. 2021; 10(7): 1461. https:dx.doi.org/10.3390/jcm10071461.
- Hay P. Bacterial vaginosis. F1000Res. 2017; 6: 1761. https://dx.doi.org/10.12688/f1000research.11417.1.
- Senok A.C., Verstraelen H., Temmerman M., Botta G.A. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst. Rev. 2009; 4: CD006289. https://dx.doi.org/10.1002/14651858.CD006289.pub2.
- Hanson J.M., McGregor J.A., Hillier S.L., Eschenbach D.A., Kreutner A.K., Galask R.P., Martens M. Metronidazole for bacterial vaginosis. A comparison of vaginal gel vs. oral therapy. J. Reprod. Med. 2000; 45(11): 889-96.
Received 29.10.2021
Accepted 11.11.2021
About the Authors
Ada T. Uruymagova, post-graduate student of the Department of Obstetrics, Gynecology, Perinatology and Reproductology, V.I. Kulakov NMRC for OGP,Ministry of Health of Russia, ada.uruimagova@yandex.ru, http://orcid.org/0000-0001-5650-3377, 4 Akademika Oparina str., Moscow, 117997, Russia.
Vera N. Prilepskaya, Dr. Med. Sci., Professor, Honored Scientist of the Russian Federation, Head of the Scientific Polyclinic Department, V.I. Kulakov NMRC for OGP,
Ministry of Health of Russia, vprilepskaya@mail.ru, http://orcid.org/0000-0003-3993-7629, 4 Akademika Oparina str., Moscow, 117997, Russia.
Elena A. Mezhevitinova, PhD, Leading Researcher of the Scientific and Polyclinic Department, V.I. Kulakov NMRC for OGP, Ministry of Health of Russia,
mejevitinova@mail.ru, http://orcid.org/0000-0003-2977-9065, 4 Akademika Oparina str., Moscow, 117997, Russia.
Andrey E. Donnikov, PhD, Head of the Laboratory of Molecular Genetic Methods, V.I. Kulakov NMRC for OGP, Ministry of Health of Russia, donnikov@dna-technology.ru, http://orcid.org/0000-0003-3504-2406, 4 Akademika Oparina str., Moscow, 117997, Russia.
Patimat R. Abakarova, PhD, Researcher at the Scientific and Polyclinic Department, V.I. Kulakov NMRC for OGP, Ministry of Health of Russia, abakarova2002@mail.ru,
http://orcid.org/0000-0002-8243-5272, 4 Akademika Oparina str., Moscow, 117997, Russia.
Elmira R. Dovletkhanova, PhD, Researcher at the Scientific and Polyclinic Department, V.I. Kulakov NMRC for OGP, Ministry of Health of Russia, eldoc@mail.ru,
http://orcid.org/0000-0003-2835-6685, 4 Akademika Oparina str., Moscow, 117997, Russia.
Kirill I. Gusakov, PhD, Researcher at the Scientific and Polyclinic Department, V.I. Kulakov NMRC for OGP, Ministry of Health of Russia, kigusakov@gmail.com,
http://orcid.org/0000-0003-3895-8225, 4 Akademika Oparina str., Moscow, 117997, Russia.
Angelina A. Odyvanova, post-graduate student of the Department of Obstetrics, Gynecology, Perinatology and Reproductology, V.I. Kulakov NMRC for OGP,
Ministry of Health of Russia, lina6345@yandex.ru, http://orcid.org/0000-0002-2826-9111, 4 Akademika Oparina str., Moscow, 117997, Russia.
Authors’ contributions: Uruimagova A.T., Prilepskaya V.N., Mezhevitinova E.A., Donnikov A.E., Abakarova P.R.,
Dovletkhanova E.R., Gusakov K.I., Odyvanova A.A.: development of the design of the investigation; obtaining the data for analysis; review of publications on the topic of the article; analysis of the findings; writing the text of the manuscript.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The article has been prepared without sponsorship.
Patient Consent for Publication: All patients provided informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Uruimagova A.T., Prilepskaya V.N., Mezhevitinova E.A., Donnikov A.E.,
Abakarova P.R., Dovletkhanova E.R., Gusakov K.I., Odyvanova A.A.
Efficiency and acceptability of two-stage therapy for recurrent bacterial vaginosis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2021; 11: 202-212 (in Russian)
https://dx.doi.org/10.18565/aig.2021.11.202-212
Similar Articles
